Duke University

University of North Carolina at Chapel Hill

Biozyme, Inc.

Pei Zhou

Eric John Toone

Robert A Nicholas

Frank Navas, Iii

Ramesh Gopalaswamy

Xiaofei Liang

Marcia Moss

Jiyong Hong

Frank Iii Navas

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, R, R, R, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds.

Benzoylglycine derivatives and methods of making and using same

This invention relates to compounds, pharmaceutical compositions comprising them, and methods of using the compounds and compositions for treating diseases related to translesion synthesis (TLS) pathway. More particularly, this disclosure relates to small molecule inhibitors of TLS, methods of inhibiting TLS pathway with these compounds, and methods of treating diseases related to the TLS pathway.

Compositions and methods for adjuvant cancer therapeutics

Disclosed are compounds of formulae: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, R, R, R, n, and m are defined herein. These compounds are useful for treating Gram-negative bacteria infections. Also disclosed are methods of making these compounds. 

Disclosed are compounds of formulae: (I), and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, R, R, R, R, R, R, D, Q, Y, X, X, X, and Xare defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

Substituted hydroxamic acid compounds

Disclosed are compounds of formulae (I), (II), and (II)I: and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, R, L, D, Q, Y, X, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

Ethynylbenzene derivatives

Disclosed are compounds of formulae (I) and (II) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, R, R, Y, Z, X, R, R, R, R, Y, Z, X, and Xare defined herein. These compounds are useful for treating Gram-negative bacteria infections, such asbacterial infections. 

Antibacterial compounds

Disclosed are compounds of formulae: (I) and pharmaceutically acceptable salts thereof, wherein the variables, R, R, Y, and Z are defined herein. These compounds are useful for treating Gram-negative bacteria infections. 

2-piperidinyl substituted N,3-dihydroxybutanamides

The presently disclosed subject matter discloses isolated ADAM 10 modulating peptides and related compounds useful for studying the biological functions of ADAM 10 and for the treatment of diseases such as cancer, neurological disorders, asthma, and allergic responses, and disorders characterized at least in part by the presence of one or more of inflammation, excess cell proliferation, angiogenesis, and excess soluble CD23. In one aspect, the presently disclosed subject matter provides isolated mouse and human ADAM 10 prodomain comprising the sequence set forth in SEQ ID NOs 1-8, or a sequence having at least 95% homology to any of SEQ ID NOs 1-8 and having the functionality of modulating ADAM 10 activity.

Growing community of inventors

Durham, NC, United States of America

Pei Zhou